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Abstract: Manipulation of the microbiome is a rational treatment strategy for inflammatory bowel
disease (IBD). Compared to the colon and terminal ileum (TI), understanding of the microbial
composition in the duodenum is sparse. This gap in knowledge is especially significant for children
with Crohn’s disease (CD) because the prevalence of duodenal CD is higher in children than in
adults. Our aim was to characterize the bacterial composition of the mucosally-adherent duodenal
microbiome in children with and without CD as a first step toward development of targeted IBD
treatment strategies at this disease location. Fresh-frozen mucosal biopsies were obtained from
the duodenum and TI of children with treatment-naïve CD and age- and sex-matched controls.
Extracted DNA was analyzed for sequence variation in the 16S ribosomal RNA bacterial gene region
V4 (Novogene; Beijing, China). Bacterial relative abundance, alpha and beta composition, and
diversity, were compared across duodenal and TI samples from the controls and CD groups with
and without chronic active inflammation (118 samples from 73 children total; approx. 50% CD),
using UniFrac dissimilarity coefficients (α < 0.05), Linear Discriminant Analysis Effect Size (LEfSe)
analysis (LDA score ≥ 2), and Unweighted Pair Group Method with Arithmetic Mean (UPGMA)
analysis. The relationships between bacterial abundance, sex, age, concomitant medication use, and
villous length were assessed. The microbial composition in the duodenum was significantly different
from the TI in the control population(R-value = 0.558, p = 0.001) and in children with active CD
(R-value = 0.301, p = 0.001). Significant differences in bacterial abundance were noted between the
control and CD duodena (LDA > 4). The duodenum of children without CD was characterized by
increased abundance in Pseudomonodales, whereas the actively inflamed duodenum in CD was
characterized by increased abundance of Bacteroidales, specifically the family Prevotellaceae. This
trend is opposite of previously published observations of microbial composition in the TI, where
active inflammation was associated with a relative decrease in the abundance of Bacteroidetes and
an increase in Proteobacteria, including Pseudomonadales. No statistically significant correlations
were noted between abundance and age, sex, concomitant medication use or villous length, except
for Bacteroidetes, which significantly decreased in abundance in the TI with age (p = 0.048). The
pediatric duodenal microbiome is distinct from the TI and characterized by an increased abundance of
Pseudomonodales and Spirochetes in healthy children, and an increased abundance of Bacteroidales
in active CD patients.
Keywords: inflammatory bowel disease; Crohn’s disease; duodenum; microbiome; pediatric; small intestine
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1. Introduction
Inflammatory Bowel Disease (IBD), with its major subtypes Crohn’s disease (CD) and
Ulcerative Colitis (UC), is a chronic disease of the gastrointestinal (GI) tract, marked by
relapsing and remitting episodes of inflammation of the intestinal mucosa [1,2]. Although
its exact etiology remains unknown, the consensus of the pathogenic model consists of a
multifactorial, dynamic dysregulation of the host immune system, genetic predisposition,
environmental triggers and dysbiosis of the intestinal microbiome [3]. Progress in understanding the role of each of these domains has been variable, and the microbiome remains
comparatively poorly understood, even though its manipulation has been identified as a
rational treatment strategy for IBD [4].
What is currently known is that the neonatal GI tract is initially colonized with flora
from the mother in-utero and/or during birth [5]. The microbiome subsequently develops
over the ensuing years, primarily in response to environmental exposures [6]. This chronological development, in combination with altering effects of other exogenic influences such
as diet, medication use, and acute and chronic illness, creates a dynamically changing
microbial composition that has proven somewhat difficult to characterize comprehensively
across the pediatric age range, as well as within specific patient populations.
To date, most studies in IBD have focused on the colon and the distal small intestine
(i.e., terminal ileum), where bacteria are most abundant. However, the proximal small
intestine (i.e., duodenum) is not sterile, and unique differences in bacterial composition can
be anticipated because different locations within the small intestine have been shown to
have different microbial compositions [7]. Understanding of the bacterial composition in the
pediatric duodenum is particularly important because duodenal pathology is more common
in pediatric onset CD, compared with adult-onset disease [8–11], raising the possibility that
dysbiosis may play a role in duodenal disease manifestation and/or treatment. Yet, to our
knowledge, no studies exist regarding the duodenal microbial composition in pediatric IBD
during disease remission vs. flare. Given this knowledge gap, we aimed to characterize
the bacterial composition of the duodenal microbiome in children with and without CD,
with and without active duodenal disease involvement. To highlight findings specific to
the duodenum, we also sequenced the terminal ilea from these children for comparison.
2. Results
2.1. Participants and Samples
In total, 146 small intestinal mucosal biopsy samples from 75 children were sent to
Novogene for 16S sequencing of the bacterial V4 region. Of these, 118 samples from
73 children passed initial quality control (QC) and were sufficiently free of contamination
from human DNA. The QC pass rate for samples from the duodenum was lower (64%)
than for the TI (93%). Ultimately, 48 duodenal samples (27 from controls and 21 from the
CD group (8 active duodenal disease, 13 inactive duodenal disease) and 68 TI samples
(33 from controls and 35 from the CD group (29 active TI disease, 6 inactive TI disease)
were available for analysis. Duodenal and TI samples from one child were specifically
excluded from statistical analysis due to discovery of concomitant acute enteric infection at
the time of study biopsy collection.
2.2. Characterization of the Duodenal Microbiome
As summarized in Table 1, the duodenal patient population (Duo) was comprised
primarily of adolescents. There were more samples from males than females across all three
Duo study groups: Control (Duo0), Active Duodenal CD (Duo1), and Inactive Duodenal CD
in the presence of active CD elsewhere (Duo2). However, differences in gender composition
did not reach statistical significance and no statistically significant differences in age were
observed across the study groups.
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Table 1. Baseline characteristics of children with and without Crohn’s Disease (CD) in the duodenum.
This study population was comprised of three subgroups based on disease activity: Control (no CD;
Duo0), CD-active (active disease in the duodenum; Duo1), CD-inactive (diagnosis of CD without active
disease in the duodenum; Duo2). SD—standard deviation; IQR—interquartile range; NA—not applicable.
Duodenal Study Group
Variables
Sex
Female
Male
Age (years)
(mean (SD))
Age (years)
(median (IQR))
Villous length (µm)
(median (IQR))
Concomitant
medications
Acid suppression
5-ASA
Antibiotics
Probiotics

p Value
(Duo0, 1, 2)

p Value
(Duo0, 1)

2 (15.4%)
11 (84.6%)

0.207

1.000

13.70 (2.73)

13.52 (2.36)

0.960

0.984

14.25
(11.75, 16.17)
498 µm
(443.00, 557.00)

13.92
(12.29, 15.88)
242 µm
(195.00, 435.50)

13.58
(12.92, 15.58)
485 µm
(448.00, 518.00)

0.960

0.984

0.003

0.003

9 (33.3%)

6 (75%)

10 (76.9%)

0.013

0.051

5 (18.5%)
0 (0.0%)
0 (0.0%)
1 (3.7%)

2 (25.0%)
0 (0.0%)
1 (12.5%)
0 (0.0%)

1 (7.7%)
1 (7.7%)
2 (15.4%)
3 (23.1%)

0.577
0.437
0.077
0.078

0.648
N/A
0.229
1.000

Control
[Duo0 (N = 27)]

Active CD
[Duo1 (N = 8)]

Inactive CD
[Duo2 (N = 13)]

12 (44.4%)
15 (55.6%)

3 (37.5%)
5 (62.5%)

13.39 (3.69)

As expected, overall concomitant medication use at the time of biopsy collection was
consistently higher in the CD group than in the controls (presumably for symptom control
prior to diagnosis), but this difference did not reach statistical significance (Table 1). No
children were receiving treatment with immunomodulating drugs at the time of biopsy, and
only one child with CD was receiving treatment with aminosalicylates. Closer inspection
of the use of concomitant medications that could potentially alter bacterial composition in
the intestine (i.e., antibiotics, probiotics, and acid suppression medications) revealed no
statistically significant difference between the CD group and controls. However, a trend in
higher probiotic and antibiotic use was identified in the CD group compared to controls
(Table 1). None of the children enrolled were following any specific diet recommendations
for CD.
As summarized in Table 2, the overall microbial composition in Duo0 was statistically
significantly different from the composition in the TI for the controls (TI0) (R-value = 0.558,
p = 0.001) and CD-Active (TI1) (R-value = 0.301, p = 0.001), but not CD-Inactive (TI2)
(R-value = 0.123, p = 0.1). Similar trends were also observed between the Duo1 and Duo2
populations compared with TI0 and TI1. Although no significant differences in the overall
bacterial composition within the duodenal microbiome were noted in controls vs. children
with CD (Table 2), within the three duodenal study groups (Duo0, Duo1 and Duo2), certain
bacterial operational taxonomic units (OTUs) were noted to be significantly dissimilar in
terms of levels of relative abundance.
Specifically, the order Pseudomonadales was noted to be significantly more abundant
in controls compared with children with active CD, who demonstrated a significant increase
in abundance of the phylum Bacteriodetes, and more specifically the family Prevotellaceae,
as defined by a Linear Discriminant Analysis (LDA) score > 4 (Figure 1).
These observations were supported in an Unweighted Pair Group Method with
Arithmetic mean (UPGMA) analysis assessing alpha and beta diversity in the duodenum (Figure 2), where we observed an 11% increase in Bacteriodetes abundance in the
duodena of children with active CD compared with the controls. In contrast, the control
duodenal microbiome appeared to be characterized by an increased abundance of Spirochetes (p-value = 0.28); however, the LDA criteria for statistical significance was not reached
for either Spirochetes or Bacteriodetes in this analysis.
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N = 29 (0.017)
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0.31
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(0.017)
(0.033)
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- and more1 specifically the family
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-

(A)
Figure 1. Cont.

1

0.668
(0.001)
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(B)
Figure 1. Linear Discriminant Analysis effect size (LEfSe) comparing relative bacterial composition
in the duodenum between controls (Duo0, red) and children with active Crohn’s disease in the
duodenum (Duo1, green). (A) The cladogram compares differences between bacterial entities in
the duodena of controls and children with active Crohn’s Disease (CD). Innermost nodes represent
the phylum level of classification and move outward to class, order, family and genus. Yellow
nodes denote bacterial entities that were not significantly different between the two duodenal
study groups. (B) Bar graph with log 10 transformed Linear Discriminant Analysis (LDA) scores
that numerically compares the most abundant bacterial taxa between controls and children with
(B)
active duodenal CD.

Figure
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These observations were supported in an Unweighted Pair Group Method with
Arithmetic mean (UPGMA) analysis assessing alpha and beta diversity in the duode
num (Figure 2), where we observed an 11% increase in Bacteriodetes abundance in the
duodena of children with active CD compared with the controls. In contrast, the contro
duodenal microbiome appeared to be characterized by an increased abundance of Spirochetes (p-value = 0.28); however, the LDA criteria for statistical significance was no
reached for either Spirochetes or Bacteriodetes in this analysis.

Figure
Unweighted
Pair-group
Method
with
Arithmetic
Mean
(UPGMA)
analysis
assess
and
Figure
2. 2.
Unweighted
Pair-group
Method
with
Arithmetic
Mean
(UPGMA)
analysis
to to
assess
and
compare
alpha
and
beta
the relative
relacompare
alpha
and
betadiversity
diversityacross
acrosstissues
tissuesand
andstudy
studygroups.
groups. The
The bar chart depicts the
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abundance
of bacteria
at the
phyla
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the largest degree of difference between Duo and TI, Duo0 & TI0-Controls, Duo1 & TI1-Active CD
degree of difference between Duo and TI, Duo0 & TI0-Controls, Duo1 & TI1-Active CD at that biopsy
at that biopsy site, and Duo2 & TI2-CD without active inflammation at that biopsy site, but present
site, and Duo2 & TI2-CD without active inflammation at that biopsy site, but present elsewhere.
elsewhere.

To further explore whether concomitant medication use could explain some of the
differences in OTU abundance observed in the duodena of children with CD vs. controls
(Figure 1), we compared OTU abundance between children receiving and not receiving
concomitant medications within each duodenal study subgroup (Duo0, Duo1 and Duo2).
No statistically significant differences were observed (Table 3).

Figure 2. Unweighted Pair-group Method with Arithmetic Mean (UPGMA) analysis to assess and
compare alpha and beta diversity across tissues and study groups. The bar chart depicts the rela
tive abundance of bacteria at the phyla level for both the duodenum (Duo) and terminal ileum
(TI). The dendrogram on the left allows comparison across tissues and study groups, highlighting
the largest degree of difference between Duo and TI, Duo0 & TI0-Controls, Duo1 & TI1-Active CD
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Table 3. Descriptive statistics for the TI sample population comprised of three study groups: Control
(TI0), CD-active (TI1), and CD-inactive (TI2). SD—standard deviation, IQR—interquartile range.
No Medication
Group

OTU

Duo0

Prevotellaceae
Bacteroidales
Bacteroidia
Pseudomonadales

Duo1

Prevotellaceae
Bacteroidales
Bacteroidia
Pseudomonadales

Duo2

Prevotellaceae
Bacteroidales
Bacteroidia
Pseudoonadales

N

Absolute
Abundance
Mean (std. dev)

18

1469.00 (1942.94)
8934.28 (9890.48)
8938.56 (9891.18)
5330.78 (6685.56)

2

2628.00 (3669.88)
5987.50 (8122.54)
5987.50 (8122.54)
451.00 (545.89)

3

833.33 (474.88)
15,216.67 (13,674.53)
15,226.00 (13,689.13)
426.00 (157.43)

p-Value

Medication
N

Absolute
Abundance
Mean (std. dev)

9

768.00 (791.71)
13,089.78 (20794.81)
13,095.89 (20802.23)
2682.33 (2566.65)

0.3116
0.4836
0.4836
0.2660

6

4097.17 (4838.70)
21,602.67 (17,613.49)
21,609.00 (17,613.25)
872.00 (1145.87)

0.7130
0.2883
0.2883
0.6466

10

2062.20 (3620.96)
13,459.40 (15,400.62)
13,473.20 (15,395.57)
2974.20 (4620.23)

0.5808
0.8629
0.8629
0.3743

2.3. Characterization of the TI Microbiome
The patient characteristics of the TI population (Table 4) were similar to the Duo
population, with slightly more males than females (not statistically significant) and no
statistically significant differences in age across the three study groups: Control (TI0), Active
TI CD (TI1), and Inactive TI CD with presence of active CD elsewhere (TI2). More patients
were included in the TI population than the Duo population, as more tissue samples passed
quality control for library preparation.
Table 4. Descriptive statistics for the TI sample population comprised of three study groups: Control
(TI0), CD-active (TI1), and CD-inactive (TI2). SD—standard deviation, IQR—interquartile range.
TI Study Group
Variables
Sex
Female
Male
Age (years)
(mean (SD))
Age (years)
(median (IQR))
Villous length (um)
(median)
Missing
Concomitant Medications
Acid Suppression
5-ASA
Budesonide
Antibiotics
Probiotics

p Value
(TI0, 1, 2)

p Value
(TI0, 1)

2 (33.3%)
4 (66.7%)

0.496

0.245

13.00 (2.55)

11.25 (6.17)

0.238

0.163

13.00
(11.58, 15.09)
241
(97.50, 367.50)
1
20 (69.0%)
4 (13.8%)
3 (10.3%)
1 (3.4%)
3 (10.3%)
26 (89.7%)
3 (10.3%)

11.74
(8.25, 15.17)
468.00
(444.00, 490.00)
1
5 (83.3%)
3 (50.0%)
0 (0.0%)
0 (0.0%)
1 (16.7%)
5 (83.3%)
1 (16.7%)

0.238

0.163

<0.001

<0.001

0.044
0.113
0.204
0.515

0.036
0.445
0.097
0.468

0.063

0.097

0.199

0.332

Control
[TI0 (N = 33)]

Active CD
[TI1 (N = 29)]

Inactive CD
[TI2 (N = 6)]

15 (45.5%)
18 (54.5%)

9 (31.0%)
20 (69.0%)

13.70 (3.51)
14.25
(11.92, 16.25)
502.00
(458.00, 552.50)
5
14 (42.4%)
7 (21.2%)
0 (0.0%)
0 (0.0%)
0 (0.0%)
33 (100.0%)
1 (3.0%)

The reported medication use at time of endoscopy was significantly higher in CD
patients (Table 4). Individual use of probiotics, antibiotics, acid suppressants, or aminosalicylates (CD only) was not significantly different across the three TI groups. No children
were receiving treatment with systemic immunomodulators at the time of biopsy, but one

Probiotics

Pharmaceuticals 2022, 15, 850

33 (100.0%)
1 (3.0%)

26 (89.7%)
3 (10.3%)

5 (83.3%)
1 (16.7%)
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As previously mentioned, significant differences in the overall bacterial composition
As previously mentioned, significant differences in the overall bacterial composiwere noted between the duodenum and TI in both the controls and in children with active
tion were noted between the duodenum and TI in both the controls and in children with
CD; however, no significant differences were noted when comparing the duodenum to the
active CD; however, no significant differences were noted when comparing the duodeTI of children with Crohn’s but no active inflammation in the TI (Table 2).
num to the TI of children with Crohn’s but no active inflammation in the TI (Table 2).
Comparison of specific bacterial OTUs between the control Duo and TI shows a signifiComparison of specific bacterial OTUs between the control Duo and TI shows a
cant increase in abundance of the class of Bacilli, and phyla of Cyanobacteria, Actinobacteria,
significant increase in abundance of the class of Bacilli, and phyla of Cyanobacteria, AcSpirochetes, and Proteobacteria, in the duodenum. Conversely, the phylum Bacteriodetes,
tinobacteria, Spirochetes, and Proteobacteria, in the duodenum. Conversely, the phylum
and the class of Clostridia, are significantly more abundant in the TI, compared with the
Bacteriodetes, and the class of Clostridia, are significantly more abundant in the TI,
duodena in controls (Figure 4).
compared with the duodena in controls (Figure 4).
2.5. Microbial Abundance, Age, Sex, and Villous Length
Age: In our primarily adolescent population, the relative abundance of bacteria did
not correlate significantly with age, except Bacteroidetes, which decreased in relative
abundance in the TI as age increased (rho = −0.32, p-value 0.027). This finding held true in
a multivariate analysis that controlled for tissue type (F (1, 43) = 4.14, p-value = 0.048).
Sex: Differences in relative abundance were not observed between sexes. The largest
difference with respect to sex and relative abundance was found in cyanobateria
(F (1, 45) = 4.14, p-value = 0.0916), but it did not reach statistical significance.
Villous Length: As mucosally-adherent bacteria reside on intestinal villi and intestinal villous length is known to vary between inflamed and non-inflamed tissue [13,14],
we explored the relationship between bacterial abundance and villous length through
Pearson correlation analysis. For both the duodenum and the TI, the median intestinal
villous length was shortest in samples from children with CD and active inflammation
(Tables 1 and 2). In the duodenum, a statistically significant negative correlation was observed for villous length and Prevotellaceae abundance (rho = −0.35; p = 0.0147) (Table 5).
However, marked variability in Prevotellaceae abundance was noted in patients with the
shortest villi (Figure 5). No significant correlations were observed between villous length
and OTU abundance in the TI (Table 6).

Pharmaceuticals
2022,
15,
Pharmaceuticals
2022,
15,850
x FOR PEER REVIEW

15
88ofof16

Figure 4. Linear Discriminant Analysis Effect Size (LEfSe) analysis results comparing duodenal
Figure 4. Linear Discriminant Analysis Effect Size (LEfSe) analysis results comparing duodenal and
and terminal ileum biopsies. The cladogram compares significant differences between species in
terminal ileum biopsies. The cladogram compares significant differences between species in the
the duodena of controls (red) and the TI controls (green). Species nodes in yellow are those that
duodena
of controls (red)
and the
controls (green).
Species
nodes
in yellow
those that areand
not
are not significantly
different.
TheTIinnermost
nodes begin
at the
phylum
level are
of classification
significantly
different.
innermost
nodes
begin
at the
move outward
to class,The
order,
family and
genus
toward
thephylum
exterior.level of classification and move
outward to class, order, family and genus toward the exterior.

2.5. Microbial Abundance, Age, Sex, and Villous Length
Table 5.
Pearson
correlation
analysis
of duodenal
villous length
and bacterial
OTU abundance.
CorrelaAge:
In our
primarily
adolescent
population,
the relative
abundance
of bacteria
did
tion
betweenwith
each age,
OTU and
villous
length, with pwhich
value reported
in parentheses.
notcoefficient
correlatereported
significantly
except
Bacteroidetes,
decreased
in relative

Villous Length
Prevotellaceae
Bacteroidales
Bacteroidia
Pseudomonadales

abundance in the TI as age increased (rho = −0.32, p-value 0.027). This finding held true
Pearsonanalysis
Correlation
N=
48 type (F (1, 43) = 4.14, p-value = 0.048).
in a multivariate
that Coefficients,
controlled for
tissue
p-Value
Sex: Differences in relative abundance were not observed between sexes. The largVillous length
Bacteroidia
Pseudomonadales
est differencePrevotellaceae
with respect to sexBacteroidales
and relative abundance
was found in
cyanobateria (F
−
0.35
−
0.11
−
0.11
0.05
(1, 45) = 4.14, p-value = 0.0916), but it did not reach statistical significance.
1.00000
(0.0147)
(0.4669)
(0.4671)
(0.7324)
Villous Length: As mucosally-adherent bacteria reside on intestinal villi and intes0.51
0.51
−0.12
1.00000
tinal villous length
is known to vary(0.0002)
between inflamed (0.0002)
and non-inflamed tissue
[13,14],
(0.4578)
we explored the relationship between bacterial abundance
through
1.00and villous length
−0.24
1.00000
Pearson correlation analysis. For both the duodenum and
the TI, the median
intestinal
(<0.0001)
(0.0947)
−0.24
villous length was shortest in samples from children with
CD and active inflammation
1.00000
(0.0947)
(Tables 1 and 2). In the duodenum, a statistically significant negative correlation was ob1.00000
served for villous length and Prevotellaceae abundance (rho = −0.35; p = 0.0147)
(Table 5).
However, marked variability in Prevotellaceae abundance was noted in patients with
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length and OTU abundance in the TI (Table 6).
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Figure 5. Scatter plot of absolute abundance of Prevotellaceae in all duodenal samples, with duo-

Figure 5. Scatter plot of denal
absolute
abundance of Prevotellaceae in all duodenal samples, with duodenal
villous lengths fit with a linear regression and 90% confidence interval (shaded area).
villous lengths fit with a linear regression and 90% confidence interval (shaded area).
Table 6. Pearson correlation analysis of TI villous length (when available) and bacterial OTU abundance. Correlation coefficient reported between each OTU and villous length, with p value reported
in parentheses.
Pearson Correlation Coefficients
p-Value
Number of Observations
Villous length
Villous Length

Prevotellaceae

Bacteroidales

Bacteroidia

Pseudomonadales

1.00000
61

Prevotellaceae
0.21871
(0.0904)
61

0.21871
(0.0904)
61
0.10402
(0.4250)
61
0.10398
(0.4252)
61
−0.11788
(0.3656)
61

1.00000
68
0.23623
(0.0524)
68
0.23622
(0.0525)
68
0.06367
(0.6060)
68

Bacteroidales
0.10402
(0.4250)
61
0.23623
(0.0524)
68
1.00000
68
1.00000
(<0.0001)
68
−0.33609
(0.0051)
68

Bacteroidia
0.10398
(0.4252)
61
0.23622
(0.0525)
68
1.00000
(<0.0001)
68
1.00000
68

−0.33608
(0.0051)
68

Pseudomonadales
−0.11788
(0.3656)
61
0.06367
(0.6060)
68
−0.33609
(0.0051)
68
−0.33608
(0.0051)
68
1.00000
68

3. Discussion
To our knowledge, this study is the first of its kind to characterize the composition
of the mucosally-adherent duodenal microbiome in children with and without Crohn’s
disease. Such characterization is necessary and represents a pivotal first step in developing
targeted treatment options for manipulating the microbiome and restoring microbial balance in the proximal small intestine. This is particularly relevant to children with Crohn’s
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disease, who are more likely than adults to have duodenal disease involvement [8–11].
First, our study demonstrates that the pediatric duodenal microbiome of healthy children
and children with Crohn’s disease appears distinct from the microbial composition in the
TI (Table 2), except for the TI of children with CD without active TI inflammation (TI2
study group). The latter observation is likely due to small sample size in the TI2 study
group (n = 6), and it is possible that differences in microbial composition may be observed
in larger studies. Second, based on our findings, the healthy pediatric duodenal microbiome is characterized by significantly increased relative abundance of Pseudomonadales,
compared with children with active duodenal CD, whose duodenal microbiome appears
characterized by significantly increased relative abundance of Bacteriodetes, specifically the
family Prevotellaceae (Figure 1). These observed differences do not appear to be related to
differences in age, sex, or concomitant medication use across or within the duodenal study
groups. Although we observed a statistically significantly inverse relationship between
villous length and Prevotellaceae abundance in the duodenum (p = 0.0147), upon closer
inspection of Figure 4, this may be an artifact stemming from the relative sparsity of patients
with short villi (<300 µm) and the marked variability in Prevotellaceae abundance within
this small subset of patients (n = 5). No significant correlations between villous length
and abundance of bacterial entities were noted in the TI (Table 6). Larger studies may be
needed to tease out the relative contribution of villous length versus active inflammation
per se to variability in mucosally-adherent bacterial abundance. We believe such studies
are possible, as we have previously demonstrated substantial inter-individual variability
in intestinal villous length in children with and without active IBD, such that children
with active disease may have intestinal villous length comparable to children with Crohn’s
disease in remission or children without Crohn’s disease [14].
While some pediatric studies of microbial composition in the duodenum have been
published for other chronic, inflammatory, gastrointestinal conditions such as celiac disease [15], few data exist for IBD. One such study of duodenal aspirates in children with
CD vs. controls observed Atopobium parvulum relative abundance to be increased in the
duodena of children with CD [16], a finding not observed in our study and likely explained
by differences in the biospecimen matrix sequenced for microbial rRNA (i.e., duodenal
aspirate vs. mucosal biopsy tissue sequenced in our study). Another study of duodenal
aspirates demonstrated decreased Firmicutes, Actinobacteria, and Bacteroidetes abundance
in the duodena of children with UC [17]. The observation of decreased Bacteroidetes in the
duodena of patients with UC in this prior work by Sjoberg et al., is the opposite of our
findings in Crohn’s disease, and consistent with previous observations of known microbiome differences between Crohn’s disease and UC [18]. Differences in study findings may
also be explained by the use duodenal aspirates in the UC study, as opposed to our use of
mucosal biopsy tissue. Although the QC pass rate for duodenal biopsy samples was lower
than for TI biopsy samples, through this study we provide important proof of concept
that duodenal mucosal biopsies can be used to characterize microbial composition in the
proximal bowel of children. We believe the observed difference in the QC pass rate between
the duodenum and TI was likely related to the generally lower abundance of bacteria in
the proximal bowel, compared with the distal bowel. With fewer bacteria present in the
duodenum than in the TI, the likelihood of bacterial genetic material contamination by host
DNA/RNA is greater; hence, the lower QC pass rate.
Similar to findings in other studies, our study demonstrates regional differences in
microbial composition across the length of the human intestine. More specifically, our
observations of increased Bacteriodetes in the control TI compared to control duodenum
are in line with prior work in adults. In a study by Vuik et al., patients undergoing
double balloon enteroscopy for undiagnosed abdominal symptoms were biopsied along
the entirety of their small intestine, with biopsies submitted for16S rRNA sequencing
demonstrating an increased relative abundance of Firmicutes and Bacteriodetes in the TI,
and increased Proteobacteria and Firmicutes in the duodenum [7]. This prior work in
adults supports our observations in the duodena of children. Although our analysis did
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not specifically demonstrate a significant difference in the relative abundance of Firmicutes,
it did show a significant increase in Bacilli, a bacterial class within the phylum Firmicutes
(Figure 4). Our observations of increased clostridia and lachnospiraceae in the TI of controls,
compared with active CD, is also in line with prior work in children by Haberman et al. [19].
The consistency of our observations in the TI with prior adult and pediatric studies of
the mucosally-adherent microbiome [7,19] lends credibility to our methodologies and our
novel microbiome findings in the pediatric duodenum.
Interestingly, our observations of decreased Bacteriodetes in healthy vs. inflamed duodena are the opposite of previous observations in the TI made by Haberman et al. [19]. Our
findings also illustrate increased relative abundance of Pseudomonadales (Proteobacteria
phylum) in the duodena of controls vs. active CD, contrary to prior observations in the
TI, where Proteobacteria abundance was increased in active IBD [19]. Notably, only TI
samples without active inflammation from patients with evidence of active colonic CD
were included in the study by Haberman et al. [19], which may help explain the difference
between our study findings and theirs. Alternatively, regional differences in the normal
healthy composition of the microbiome in the duodenum vs. TI may explain this trend
reversal between the two disease locations in the small intestine in active CD. The significance of this reversal in abundance between the duodenum and TI remains uncertain and
warrants further investigation to help determine what roles Proteobacteria may play in
inflammatory pathogenesis versus disease protection. Our findings suggest that the role
of these OTUs in microbial homeostasis may differ depending on the location within the
small intestine.
Comparing our study findings to other works describing the ileal mucosal microbiome,
Assa et al. demonstrated an increase in OTU abundance of Faecalibacterium prausnitzii (genus
of Ruminococcus and class Clostridia) in a small study of 10 pediatric patients with newly
diagnosed CD compared with controls [20]. We observed the opposite trend in our larger
pediatric cohort, where controls (n = 33) demonstrated increased Clostridia abundance
compared with children with active CD in the TI (n = 29). The abundance of F. prausnitzii
and Ruminococcus, specifically, was not observed to be significantly different between
controls and children with active CD jn the TI in our study. Sequencing of different bacterial
regions between studies (V4 in our study vs. V6 in the study by Assa et al.) could contribute
to this difference in study findings.
Previous studies have demonstrated differences in microbial composition of the
mucosally-adherent microbiome in the TI of active vs. inactive CD, as well as controls [19].
In our study, we noted a significant difference in the overall bacterial composition in the
TI of Controls vs. children with active CD, but we did not find significant differences in
the TI microbial composition between active and inactive CD (Table 2). These observations
may be due to the limitations of the small sample size for the CD Inactive study group
(n = 6), as differences were detected in the two larger study groups in the TI (Control TI
n = 33, CD Active TI n = 29), but not for the smaller CD Inactive study group. Similarly,
the lack of differences in the overall bacterial composition across the three duodenal study
arms is likely due to the small sample sizes in CD Active (n = 8) and CD Inactive (n = 13).
Another potential limitation in our study is the lack of available information regarding
the typical diet history for individuals enrolled in this investigation, as diet is a known
contributor to microbial differences in the human intestine [21]. However, we believe this
is mitigated by an important strength of our investigation design. By specifically analyzing
the mucosally-adherent microbiome, we aimed to minimize, as much as possible, potential contamination of the sequenced microbiome by confounders such as xenobiota from
the diet, which may remain residually in luminal secretions and could be inadvertently
collected during duodenal aspiration.
Previous studies of the intestinal microbiome have shown that environmental exposures, such as diet and medication use, alter microbial composition [22,23]. As expected,
concomitant medication use was significantly higher in children with CD vs. controls in
our investigation, likely due to the need for symptom management of previously undi-
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agnosed or inadequately treated disease in the CD population. However, examination
of the contribution of individual drugs (e.g., antibiotics, probiotics, acid suppressors) to
variability in the microbiome in the duodenum and TI revealed no significant differences
between those receiving and not receiving individual medications (Tables 1 and 4). Given
the relatively small sample size in our study, we were likely underpowered to detect the
influence of concomitant medication use on variability in microbial composition in the
small intestine. The cross-sectional design of our study limited the ability to determine past
antibiotic or probiotic use that may still have affected the microbiome composition on the
day of biopsy. We also acknowledge that detailed diet information, which was not collected
as part of this investigation, could also contribute to explaining the microbial findings
observed. In attempt to minimize the confounding influence of diet, all patients were
fasting at the time of biopsy and we did not include any patients following a specialized
IBD diet. Another potential limitation of our study is the use of biopsies from children
with functional GI symptoms for comparison with IBD, instead of biopsies from healthy,
asymptomatic volunteers. However, the nature of pediatric research makes obtaining
biopsies for research purposes from asymptomatic healthy children unethical.
Although our study is limited by a relatively small sample size of 73 children, it
provides important proof of capability for sequencing microbial rRNA from pediatric
mucosal biopsies from the duodenum, where microbial abundance is significantly lower
than in the TI or the colon. Our findings suggest that trends in bacterial abundance in
health and active Crohn’s disease may be reversed between the duodenum and TI, at least
for members of the phylum Proteobacteria. In contrast to observations in the adult and
pediatric TI, dysbiosis associated with duodenal Crohn’s disease is characterized by an
increased relative abundance of Bacteriodetes, compared with pediatric controls. Studies
such as ours represent an important step in understanding the role of specific OTUs in
microbiome homeostasis and are essential for developing rational therapeutic strategies
for targeted microbiome manipulation for the treatment of Crohn’s disease in the small
intestine. This is particularly important for children, who are more likely than adults to be
affected by the upper tract disease [8–11].
4. Materials and Methods
4.1. Participants
Potential study participants were identified via review of the clinical endoscopy schedule and the electronic medical record (EMR) at the Children’s Mercy Hospital (CMH), a
tertiary regional pediatric hospital in the midwestern United States. The subjects were
recruited on the day of procedure, prior to endoscopy. All the subjects were fasting at
least 8 h for procedural purposes as part of routine medical care. Only those subjects
who provided informed consent (if 18 years of age or older), or informed assent with
parental/legal guardian consent (if under 18 years of age) were included. All research activities were approved by the CMH Institutional Review Board and conducted in accordance
with the ethical standards of the Declaration of Helsinki. In order to be considered for
study inclusion, children had to be between 2 and 18 years of age (inclusive), undergoing
both upper and lower endoscopy with biopsies for clinical purposes, have a reasonable
clinical suspicion for a new diagnosis of IBD or another clinical indication for undergoing
endoscopy (e.g., abdominal pain), and not receiving systemic immunomodulating, immunosuppressive, or biological drugs. Children with an established diagnosis of IBD who
were not yet receiving treatment with systemic immunomodulating, immunosuppressive,
or biological agents were eligible to enroll. All concomitant medication use at the time of
endoscopy was recorded.
The diagnosis of Crohn’s disease was established by agreement by two independent,
experienced, pediatric gastroenterologists on review of the EMR post-endoscopy, and two
independent, experienced, pediatric pathologists on histopathologic review of biopsies
collected for clinical purposes. Based on the histopathologic review, the Crohn’s disease
patients were sorted into study arms based on evidence of active inflammation in the duo-
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denal biopsies (Duo1) versus active inflammation elsewhere within the GI tract but normal
duodenal histology (Duo2). TI study arms were designated using the same approach. Once
the cohort of children with Crohn’s disease was finalized, sex-matched and age-matched
(within 12 months) controls without IBD were selected from a pool of enrolled children who
were ultimately diagnosed with functional/psychosomatic etiologies, without evidence
of inflammation or other histopathology (e.g., celiac disease) at any of the sites biopsied
for clinical purposes (i.e., esophagus, stomach, small and large intestine). Assessment
and agreement on control designation (Duo0 for duodenal and TI0 for TI biopsies) was
performed by the same two pathologists and gastroenterologists as above.
4.2. Sample Collection
Up to four mucosal biopsies were collected for study purposes from the duodenum
and TI from all participants, in close proximity to the location of biopsies obtained for
clinical purposes. Fresh tissue samples collected for research purposes were flash-frozen
and stored appropriately at −70 ◦ C until batch analysis.
4.3. DNA/RNA Extraction and Microbial Sequencing
Using the Allprep DNA/RNA/miRNA extraction kit (Qiagen, Valencia, CA, USA)
according to manufacturer’s recommendations, total DNA was extracted from intestinal
mucosal biopsy samples collected for study purposes. The DNA quantity was determined
with a NanoDrop ND-1000 spectrophotometer (ThermoFisher Scientific, Waltham, MA,
USA). Total DNA (150 ng) was submitted to a commercial service provider for analysis of
sequence variation in the 16S ribosomal RNA (rRNA) bacterial gene region V4 (Novogene;
Beijing, China).
Amplicon Generation: 16S rRNA genes of the V4 region were amplified using primer
515F-806R. All the PCR reactions were carried out with Phusion® High-Fidelity PCR Master
Mix (New England Biolabs, Ipswich, MA, USA).
PCR Products quantification and qualification: Equal volumes PCR product and 1X
loading buffer (containing SYB green) were mixed for electrophoresis on 2% agarose gel for
detection. Samples with the bright main strip between 400 and 450 base pairs (bp) were
chosen for further experiments.
PCR Products Mixing and Purification: The PCR products were mixed in equidensity
ratios. Then, the mixture of PCR products was purified with Qiagen Gel Extraction Kit
(Qiagen, Hilden, Germany).
The initial quality control analysis revealed some contamination from host genomic
DNA, which was not unexpected. The tissue samples were subjected to an additional
clean-up step to remove contaminating host genomic DNA. All the samples that passed
the quality control analysis were subsequently utilized for library preparation.
Library Preparation: Sequencing libraries were generated usingNEBNext Ultra DNA
Library Pre® Kit for Illumina following the manufacturer’s recommendations, and index
codes were added. The library quality was assessed on the Qubit@ 2.0 Fluorometer (Thermo
Scientific, Waltham, MA, USA) and Agilent Bioanalyzer 2100 system. Finally, the library was
sequenced on an Illumina platform Hiseq 2500 and 250 bp paired-end reads were generated.
4.4. Villous Length Measurement
The mucosal microbiome adheres to intestinal villi, the length of which varies with
age, location along the GI tract, and inflammation/degree of blunting from disease [13,14].
In order to explore relationships between bacterial abundance and intestinal villous length,
Infinity Analyze Software (Teledyne Lumenera, Ottawa, ON, Canada) was used to measure
the villous length, as previously described by our group [14]. Briefly, the distance from
the villous tip to its base, where it curves into the crypt, was measured in micrometers by
drawing a line between these two points.
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4.5. Data Analysis
Descriptive statistics were generated for all included study participants and tissue
samples. Microbial OTU data generated by Novogene was assessed for relative bacterial
abundance, alpha and beta composition, and overall diversity using Unifraq dissimilarity
coefficients and Linear Discriminant Analysis Effect Size (LefSe). A p value of <0.05 was
considered statistically significant for all analyses.
The overall composition of the microbiome was compared across the various study
groups, in both the terminal ileum and the duodenum. The contribution of potential
exposures to concomitant antibiotics, probiotics, acid suppressors and other non-systemic
immunomodulators to differences in microbial composition was also assessed through
Fisher’s Exact tests and two-sided T-tests. The influence of sex, age, and villous length
was also evaluated this way. Additionally, villous length across the disease subgroups was
compared in the duodenum and TI using Kruskal–Wallis tests. Since mucosally-adherent
bacteria reside on intestinal villi, the relationships between intestinal villous lengths and
microbial abundance in each of the study groups in the Duo and TI were explored using
Pearson correlation in order to interrogate the potential effect of villous blunting on CD
microbiome diversity and abundance. Lastly, multivariate analysis was performed to
investigate microbial abundance variations between the controls and CD while controlling
for age, sex, concomitant medication use, and villous length. Analyses were completed
using Novogene’s analytics, and additionally through SAS Version 9.4 (SAS Institute, Cary,
NC, USA).
5. Conclusions
This is the first study of its kind to characterize and compare the mucosally-adherent
microbiome of the duodenum in pediatric patients with and without Crohn’s disease.
Based on our data, the pediatric duodenum demonstrates increased Pseudomonadales and
Spirochetes in healthy mucosa compared with those patients with active duodenal CD,
who demonstrate increased Bacteroidetes.
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